Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells $58,093.42 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Nur Nicholson sold 2,618 shares of the stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $22.19, for a total transaction of $58,093.42. Following the sale, the insider directly owned 81,046 shares in the company, valued at $1,798,410.74. This trade represents a 3.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Apellis Pharmaceuticals Stock Down 2.9%

APLS stock opened at $19.94 on Friday. Apellis Pharmaceuticals, Inc. has a one year low of $16.10 and a one year high of $31.17. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54. The firm’s fifty day moving average is $22.89 and its 200 day moving average is $23.45. The firm has a market cap of $2.52 billion, a PE ratio of 64.32 and a beta of 0.31.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Thursday, October 30th. The company reported $1.67 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.64. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The business had revenue of $458.58 million during the quarter, compared to the consensus estimate of $364.58 million. During the same quarter in the prior year, the firm posted ($0.46) earnings per share. The company’s revenue was up 133.0% compared to the same quarter last year. On average, research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Parallel Advisors LLC lifted its position in Apellis Pharmaceuticals by 80.0% during the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock worth $33,000 after buying an additional 855 shares in the last quarter. Jones Financial Companies Lllp increased its stake in shares of Apellis Pharmaceuticals by 206.8% in the 3rd quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock worth $46,000 after acquiring an additional 1,373 shares during the last quarter. Osaic Holdings Inc. raised its holdings in shares of Apellis Pharmaceuticals by 141.2% during the 2nd quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock worth $47,000 after acquiring an additional 1,570 shares during the period. Allworth Financial LP boosted its position in shares of Apellis Pharmaceuticals by 64.1% during the 3rd quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock valued at $50,000 after acquiring an additional 857 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of Apellis Pharmaceuticals in the third quarter valued at about $64,000. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

APLS has been the subject of a number of recent analyst reports. Needham & Company LLC cut their price objective on Apellis Pharmaceuticals from $29.00 to $28.00 and set a “buy” rating for the company in a research report on Tuesday, January 13th. Robert W. Baird boosted their price target on shares of Apellis Pharmaceuticals from $50.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. JPMorgan Chase & Co. reduced their price objective on shares of Apellis Pharmaceuticals from $40.00 to $36.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Mizuho dropped their target price on shares of Apellis Pharmaceuticals from $24.00 to $19.00 and set a “neutral” rating on the stock in a research report on Monday, November 3rd. Finally, Cantor Fitzgerald reduced their price target on shares of Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating for the company in a research report on Tuesday, January 13th. Eleven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $33.65.

Key Headlines Impacting Apellis Pharmaceuticals

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: Wells Fargo reiterated a Buy on Apellis, signaling continued confidence in the company’s longer‑term commercial execution and pipeline upside — a supportive voice for holders focused beyond near‑term sales. Read More.
• Positive Sentiment: Stifel Nicolaus issued a Buy on APLS (or reiterated constructive coverage), adding a second favorable analyst view that could help stabilize valuation if execution improves. Read More.
• Neutral Sentiment: Analysts remain mixed on Apellis: some see upside from Syfovre rollout and nephrology expansion while others emphasize near‑term sales risk and valuation — expect continued divergent research notes and volatile price reactions to company updates. Read More.
• Negative Sentiment: Apellis reported preliminary Q4 U.S. net product revenue of $190M and flagged weaker Syfovre sales with mixed Empaveli uptake — the main near‑term driver cited for a recent sharp weekly decline in the stock. Read More.
• Negative Sentiment: Major research houses (Cantor Fitzgerald, Needham) issued more pessimistic forecasts or lowered expectations, increasing downward pressure by reducing modeled revenues and price targets. Read More. Read More.
• Negative Sentiment: Significant insider selling on Jan. 13: multiple senior execs (CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others) sold shares at ~ $22.19 — filings show they still retain large stakes but the volume of disposals can be perceived negatively by the market. Read More.
• Negative Sentiment: Options flow indicated a large spike in put buying (reported >500% increase in put volume), reflecting elevated hedging and bearish positioning that can amplify short‑term volatility and downside pressure. Source: options flow reports

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.